Share Price, page-6202

I think one of the issues is the conditions being targeted are all such low incidence. Journalists, clinicians and the the public are essentially self-interested in the whole. The clinician self interest is about break-through treatments in their own field. Often public interest in treatments is related to their direct connection, ie affected by a condition, or have a link to someone affected (I've done some research in this area). I envisage, after a couple of phase 2 positive results, further adding to proof of concept for 2591, that more generalised ( on likely medical efficacy) statements will start to be issued. Once headlines start including autism, cognitive decline, brain trauma, etc there will be interest in all 3 categories of a scale we cant imagine at this stage.